A novel allelic variant of the human serotonin transporter gene regulatory polymorphism (original) (raw)

Skip Nav Destination

Article navigation

1997

This article was originally published in

Cytogenetics and Cell Genetics

Issue Cover

Research Articles| May 20 2008

S.J.W. Delbrück;

aGenome Research, Max-Delbrück-Center for Molecular Medicine, Berlin (Germany);

Search for other works by this author on:

B. Wendel;

aGenome Research, Max-Delbrück-Center for Molecular Medicine, Berlin (Germany);

Search for other works by this author on:

I. Grunewald;

aGenome Research, Max-Delbrück-Center for Molecular Medicine, Berlin (Germany);

Search for other works by this author on:

T. Sander;

bDepartment of Psychiatry, Free University of Berlin, Berlin (Germany);

Search for other works by this author on:

D. Morris-Rosendahl;

cInstitute of Human Genetics and Anthropology, University of Freiburg, Freiburg (Germany);

Search for other works by this author on:

M.A. Crocq;

dFORENAP, Centre Hospitalier, Rouffach (France); and

Search for other works by this author on:

W.H. Berrettini;

eDepartment of Psychiatry and Human Behavior, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA (USA)

Search for other works by this author on:

M.R. Hoehe

aGenome Research, Max-Delbrück-Center for Molecular Medicine, Berlin (Germany);

Search for other works by this author on:

Cytogenetics and Cell Genetics (1997) 79 (3-4): 214–220.

Content Tools

Abstract

Allelic variation of the human serotonin transporter gene (SLC6A4) has recently been shown to modulate anxiety-related traits. A tandemly repeated sequence in close proximity to the promoter was found to be represented by a long (L) and short (S) variant, differentially modulating gene expression in vitro. Specifically, allele S, generated by a deletion of 44 bp involving repeats VI to VIII, reduced transcriptional efficiency, gene expression, and 5-hydroxytryptamine uptake and was associated with increased neuroticism scores. We have now identified a novel allelic variant of this promoter-linked polymorphism that is significantly larger than the L allele and which we have designated allele XL (for “extra large”). Sequence analysis revealed that XL arose through duplication of an internal segment composed of repeat elements VI to IX, comprising 85 bp in total, and, most notably, including the segments deleted in the S allele. Additional allelic variants larger than human allele L were observed predominantly in various nonhuman primates. Preliminary data indicated that these variable allelic extensions similarly originate from this specific repeat region. These allelic variants may serve as a valuable model system to further elucidate the relationship between repeat structure, regulatory properties, and behavioral correlates. Finally, allelic variants were found to vary significantly among different human populations, with allele XL being uniquely present in individuals of African origin, allele L most frequent in Africans and Caucasians of Western European descent, and allele S most abundant in East Asians.

This content is only available via PDF.

© 1997 S. Karger AG, Basel

1997

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

You do not currently have access to this content.

Sign in

Digital Version

Pay-Per-View Access

$39.00

1 Karger Article Bundle Token

$150

Rental

This article is also available for rental through DeepDyve.